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ABSTRACT 
Approximately 70% of breast cancers express estrogen receptor α (ERα), which plays 
critical roles in breast cancer development. Most of them respond to endocrine therapies 
such as anti-estrogens and aromatase inhibitors. Fulvestrant is anti-estrogen and known 
as a pure estrogen receptor antagonist, which binds to ERα with high affinity, degrades 
ERα protein, sequentially represses ERα target genes, and inhibits ERα-driven cell 
growth. In ERα positive, postmenopausal advanced breast cancer, fulvestrant is effective 
not only for second-line situation after aromatase inhibitor, but also effective for first-
line situation. Fulvestrant has been effectively used to treat ERα-positive breast cancer, 
although resistance remains a critical problem. To elucidate the mechanism of resistance 
to fulvestrant, fulvestrant-resistant cell-lines named MFR (MCF-7 derived fulvestrant 
resistance) and TFR (T-47D derived fulvestrant resistance) were established from the 
ERα-positive luminal-like breast cancer cell lines MCF-7 and T-47D, respectively. Both 
fulvestrant-resistant cell lines lost sensitivity to estrogen and anti-estrogens. I observed 
diminished ERα expression at both the protein and mRNA levels. To address the 
mechanism of gene expression regulation, I examined epigenetic alteration, especially 
the DNA methylation level of ERα gene promoters. MFR cells displayed high methylation 
levels upstream of the ERα gene, whereas no change was observed in TFR cells. Hence, 
I examined the gene expression plasticity of ERα, as there are differences in its 
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reversibility following fulvestrant withdrawal. ERα gene expression was not restored in 
MFR cells, and alternative intracellular phosphorylation signals were activated. By 
contrast, TFR cells exhibited plasticity of ERα gene expression and ERα-dependent 
growth; moreover, these cells were re-sensitized to estrogen and anti-estrogens. The 
difference in epigenetic regulation among individual cells might explain the difference in 
the plasticity of ERα expression. I also identified an MFR cell-activating HER/Src-
Akt/MAPK pathway; thus, the specific inhibitors effectively blocked MFR cell growth. 
This finding implies the presence of multiple fulvestrant resistance mechanisms and 
suggests that the optimal therapies differ among individual tumors as a result of 
differing epigenetic mechanisms regulating ERα gene expression. 
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1. Introduction 
Estrogen receptor α (ERα) plays critical roles in breast cancer development and prognosis 
[1–3]. ERα belongs to the nuclear receptor super family, serves as a ligand-activated 
transcription factor, and consequently regulates target gene expression [4,5]. 
Approximately 70% of breast cancers express ERα, and most of them respond to 
endocrine therapies, such as anti-estrogens (AEs) and aromatase inhibitors (AIs), which 
target ERα signals [6,7]. AEs work as competitive inhibitors of estrogen and block ERα 
function. The selective estrogen receptor modulators such as tamoxifen block estrogen 
binding sterically, whereas selective estrogen receptor down-regulator (SERD) such as 
fulvestrant block ERα activity and degrade ERα protein. AIs affect the enzyme aromatase 
and block estrogen synthesis from androgens. For ERα positive breast cancer, treatment 
option depends on menstrual state, stage of cancer, TNM classification and so on. The 
SERM tamoxifen is frequently used in pre-menopausal case, AI is the first choice for 
treatment in postmenopausal adjuvant case, and chemotherapy is used in life-
threatening case. Endocrine therapies have been effective and associated with fewer 
adverse effects compared to chemotherapy; thus, they are widely used to treat ERα-
positive breast cancers. However, some ERα-positive cancers acquired resistance under 
long-term treatment through various mechanisms, including the repression of ERα 
expression and activation of other pathways [8–10]. To date, the SERD fulvestrant has 
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been applied to treat recurrent breast cancer, including cases of canonical AE, tamoxifen, 
or AI failure [11].  
Moreover, there are 3 important clinical trials (CONFIRM, FIRST, FALCON trials) about 
fulvestrant application. The CONFIRM trial compared the efficacy of fulvestrant 500 mg 
regimen with that of fulvestrant 250 mg per month for treatment of postmenopausal 
women with estrogen receptor-positive advanced breast cancer. The results showed that 
fulvestrant 500 mg was associated with a statistically significant increase in progression 
free survival (PFS) and not associated with increased toxicity. After then, the First-Line 
Study Comparing Endocrine Treatments (FIRST) trial had performed for 
postmenopausal women with estrogen receptor-positive, locally advanced / metastatic 
breast cancer who had no previous therapy for advanced disease received either 
fulvestrant 500 mg or aromatase inhibitor, anastrozole 1 mg. The results suggested 
fulvestrant 500 mg extends overall survival compared to anastrozole. This findings led 
the larger phase III FALCON (Fulvestrant and Anastrozole Compared in Hormonal 
Therapy Naïve Advanced Breast Cancer) trial, which demonstrated improved 
progression-free survival with fulvestrant 500 mg so far. The FIRST and FALCON trial 
suggested that fulvestrant is associated with better clinical outcomes than AI in the first-
line setting [12–14]. Therefore, it will be interesting to use fulvestrant in the first-line 
setting for ERα-positive breast cancer. 
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Fulvestrant is known as a pure estrogen receptor antagonist, which binds to ERα with 
high affinity, degrades ERα protein via the ubiquitin–proteasomal system, sequentially 
represses ERα target genes, and inhibits ERα-driven cell growth [15,16]. Although 
fulvestrant is a potent and well-tolerated drug for treating breast cancer, resistance 
occurs similarly as noted for other endocrine therapies. As a pure anti-estrogen, 
fulvestrant degrades ERα; thus, problem of acquired resistance results in greater 
mortality than that observed with other drugs. In past reports, a few groups established 
and analyzed fulvestrant-resistant cell lines [8,17–20]. Lykkesfeldt and colleagues 
reported that a fulvestrant-resistant cell line established from T-47D cells displayed a 
change in survival signaling from ERα/HER signals to HER/Src signals, and resistant 
cells generated from MCF-7 cells also illustrated that the HER family and its 
downstream signals are essential for fulvestrant resistance [17]. However, there are few 
reports describing the relationship between ERα regulation and fulvestrant resistance. 
To address this challenge, my affiliate laboratory had established fulvestrant-resistant 
cell lines from two representative luminal-like breast cancer cell lines, MCF-7 and T-47D. 
They were previously modified by predecessors of affiliate laboratory to be able to 
monitor ERα activity through fluorescent microscopy via stable transfection of estrogen 
response element (ERE)-green fluorescent protein (GFP)  [21,22]. I have characterized 
these cell lines from the viewpoint of ERα activity and regulation of ERα gene 
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transcription. 
 
2. Aim 
I aimed to elucidate the fulvestrant resistance mechanisms, especially focusing on ERα 
gene regulation, and obtain basic knowledge to establish therapeutic strategies. 
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3. Materials and methods 
3.1 Reagents 
Estradiol (E2), 4-hydroxytamoxifen, fulvestrant, and 5′-aza-2′-deoxycytidine (Aza) were 
purchased from Sigma–Aldrich (St. Louis, MO, USA), LY294002, U0126, and dasatinib 
were obtained from Cell Signaling Technology (Danvers, MA, USA). Everolimus was 
procured from LC Laboratories (Woburn, MA, USA), and lapatinib was acquired from 
Selleck Chemicals (Houston, TX, USA). The sources of antibodies for Western blotting 
were as follows: total ERα (H-184) was obtained from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA, USA), and phospho-p44/42 MAPK (Erk1/2), total MAPK (Erk1/2), 
phospho-Akt (Thr308), total Akt, and β-tubulin were acquired from Cell Signaling 
Technology. Secondary antibodies conjugated with alkaline phosphatase were purchased 
from Bio-Rad Laboratories Inc. (Hercules, CA, USA).  
 
3.2 Cells and cell culture 
MCF-7 and T-47D breast cancer cells were stably transfected with ERE-GFP reporter 
plasmids by predecessors of affiliate laboratory as reported previously and named MCF-
7-E10 (hereafter, MCF-7) and T-47D-TE8 (hereafter, T-47D), respectively [22,23]. GFP 
fluorescence was monitored by fluorescence microscopy (Leica DM, Leica Microsystems 
GmbH, Wetzlar, Germany) and visualized using a BZ-9000 (KEYENCE, Tokyo, Japan). 
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MCF-7 and T-47D cells were maintained in RPMI1640 medium (Sigma–Aldrich) 
containing 5% fetal calf serum (FCS; Gibco BRL, Grand Island, NY, USA) and 100 U/ml 
penicillin / 100μg/ml streptomycin (Gibco). MCF-7 and T-47D cells were cultured in 
fulvestrant-supplied medium (final concentration: 10 nM) for 6 months to establish 
fulvestrant-resistant cell lines. These cell lines were maintained in fulvestrant-supplied 
medium (final concentration: 10 nM). In the long-term fulvestrant withdrawal assay, 
fulvestrant cell lines were cultured in RPMI1640 containing 5% FCS and E2 (final 
concentration: 10 nM) to boost the FCS-derived E2 concentration. All cells were 
incubated at 37°C in an atmosphere containing 5% CO2. 
 
3.3 Establishment of fulvestrant resistant cell lines 
The fulvestrant cell lines had established by predecessors of affiliate laboratory and I 
have characterized these cell lines from the viewpoint of ERα activity and regulation of 
ERα transcription. The single colony isolated, ERE-GFP reporter plasmid transfected 
MCF-7 and T-47D breast cancer cell lines were used as parent cell lines. To establish 
fulvestrant cell lines, these cells were treated with fulvestrant 10nM or 100nM supplied 
medium. The dose of fulvestrant was decided referring to pharmacokinetic parameters 
obtained from clinical trials (fulvestrant 500mg regimen, Cmax - Cmin: 48.5 nM - 18.8 nM). 
The medium was changed twice a week and cells were passaged by 80% confluency. 
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During the establishment of resistant cell lines, the cells with fulvestrant 100nM 
supplied condition were all perished and resistant cells were established only from 
fulvestrant 10nM supplied condition. The established cells were used and stocked in bulk 
condition, thus they might have polyclonal character.  
 
3.4 Cell proliferation assay  
In estrogen sensitivity assays, MCF-7, T-47D, and resistant cell lines were pre-cultured 
in Phenol red-free RPMI (Gibco) supplemented with 5% dextran-coated charcoal-treated 
FCS as a steroid-depleted medium for 3 days. Cells were seeded in 24-well culture plates 
with E2 for 4 days. Cells were then harvested and counted using a Sysmex CDA-500 
automated cell counter (Sysmex, Kobe, Japan). In inhibitor sensitivity assays, all cell 
lines were maintained in RPMI1640 medium containing 5% FCS, seeded in 24-well 
culture plates with each drug for 4 days, harvested, and counted using a Sysmex CDA-
500.  
 
3.5 Real-time RT-PCR 
Total RNA was extracted using IsoGen lysis buffer (Nippon Gene, Toyama, Japan) 
according to the manufacturer’s instructions. Extracted RNA was converted to cDNA 
using a QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). Transcripts 
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were detected using a Step One™ Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA). Relative copy numbers were calculated from a standard curve and 
normalized to housekeeping genes. Transcription products from various ERα gene 
promoters were measured using specific primers for promoters A–D and to determine 
occupancy of ERα mRNA promoter sites among promoters A–D, variant mRNAs were 
determined and cumulatively gave similar estimates to that of total ERα mRNA 
expression. This methods were established by predecessors of affiliate laboratory and 
described previously [24]. The sequences of primers and probes are listed in Table 1. 
 
3.6 Western blot analysis 
Cell lysates were prepared using Lysis-M Reagent (Roche Diagnostics GmbH, Mannheim, 
Germany) supplemented with the Phos STOP phosphatase inhibitor cocktail (Roche 
Diagnostics GmbH) according to the manufacturer’s instructions. Extracted proteins 
were separated on SDS-PAGE using acrylamide gels, and proteins were transferred to 
PVDF membrane. The expression of proteins was determined by Western blotting with 
specific antibodies listed in the Reagents, and expression signals were detected on an 
ImageQuant™ LAS 4000 image analyzer (GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden) using Immun-star AP substrate (Bio-Rad). Densitometry was performed as 
shown in Figure 8A, and these results are shown under the membrane pictures. These 
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values were relative to the intensity obtained from the control.  
 
3.7 Sodium bisulfite genomic sequencing 
Genomic DNA was extracted using a DNA Mini Kit (Qiagen) and then subjected to 
sodium bisulfite treatment using an EpiTect Bisulfite Kit (Qiagen) according to the 
manufacturer’s instructions. Converted DNA was then amplified using bisulfite-specific 
PCR to obtain products for sequencing. PCR products were then gel-purified using a 
QIAquick Gel Extraction Kit (Qiagen), and direct sequencing was performed using a 
BigDye® Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and a 3500xL 
Genetic Analyzer (Applied Biosystems). Sequence data were then analyzed using 
Sequence Scanner Software 2 (Applied Biosystems), and DNA methylation levels were 
determined in three stages by comparing the sequence peaks. The CpG percentage and 
PCR primers were obtained using MethPrimer [25]. The sequences of primers and probes 
are listed in Table 2. In direct sequencing, there are limitation that I could not analyze 
all of CpGs between PCR forward primer and reverse primer. In precise, I could analyze 
22 out of 29 CpGs in region1, 18 out of 20 in region2, 6 out of 7 in region3, and all CpGs 
in region4 and 5. In colony sequencing, gel-purified PCR products were inserted into T-
easy vectors (Promega Corporation, Madison, WI, USA). They were transformed into 
competent JM109 cells (TaKaRa Bio Inc., Otsu, Japan). Colonies were then selected on 
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lysogeny broth–ampicillin (100 µg/µl) agar using the IPTG/X-gal method, and plasmid 
DNA was subsequently extracted using a QIAprep Spin Miniprep kit (Qiagen). 
Sequencing were performed as described above using M13 universal primers. 
 
3.8 DNA sequencing for ERα LBD mutation search 
Total RNA was extracted using IsoGen lysis buffer (Nippon Gene, Toyama, Japan) 
according to the manufacturer’s instructions. Extracted RNA was converted to cDNA 
using a QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). cDNA was then 
amplified by PCR to obtain products for sequencing. The primer set for PCR was as 
follows: Forward, 5′-AGC ACC CTG AAG TCT CTG GA-3′; Reverse, 5′-TGG TGC ATG 
ATG AGG GTA AA-3′. PCR products were then gel-purified using a QIAquick Gel 
Extraction Kit (Qiagen), and direct sequencing was performed using a BigDye® 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and a 3500xL Genetic 
Analyzer (Applied Biosystems). Sequence data were then analyzed using Sequence 
Scanner Software 2 (Applied Biosystems) 
 
3.9 Statistical analyses 
Student’s t-test was used to assess the significance of differences between two groups 
performed in triplicate. Data were expressed as means ± SD. P < 0.05 was considered 
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significant. 
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4. Results 
4.1 The effect of fulvestrant on ERα expression 
To confirm the effect of fulvestrant on ERα expression, I conducted short-term fulvestrant 
exposure in MCF-7 and T-47D cells. These cell lines were treated with 100 nM fulvestrant 
for 48 h, after which the medium was switched to medium lacking fulvestrant, and cells 
were harvested at the indicated time points (Fig. 1A). I monitored the change of ERα 
protein and mRNA expression using Western blotting and real-time RT-PCR, respectively. 
After 48-h treatment with fulvestrant, ERα protein expression was diminished, then it 
gradually recovered over 2 weeks under fulvestrant-withdrawn conditions (Fig. 1B). 
Conversely, ERα mRNA expression did not significantly change (Fig. 1C). This suggested 
that fulvestrant degraded ERα protein and did not affect ERα gene transcription upon 
short-term exposure. 
 
4.2 Establishment of fulvestrant-resistant cell lines 
To elucidate the fulvestrant resistance mechanisms, fulvestrant-resistant cell lines 
were established by predecessors of affiliate laboratory from MCF-7 and T-47D cells. 
The cells were cultured in fulvestrant-supplied medium (10 nM) for 6 months (Fig. 2A) 
to establish the MCF-7 derived fulvestrant resistance (MFR) and T-47D derived 
fulvestrant resistance (TFR) cell lines. Then, I examined ERα activity via GFP 
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expression using fluorescent microscopy. Both cell lines exhibited diminished GFP 
florescence, indicating a loss of ERα activity (Fig. 2B). I also analyzed estrogen and AE 
sensitivity via cell proliferation assays. Both cell lines lost sensitivity to fulvestrant and 
tamoxifen (Fig. 2C). Compared to their parent cell lines, they did not respond to 
estrogen stimulation (Fig. 2D). The fulvestrant-resistant cell lines appeared to 
proliferate in an estrogen–independent manner. 
 
4.3 Fulvestrant-resistant cell lines and genetic alteration of ERα 
First I examined genetic alteration of ERα, specifically ligand-binding domain (LBD) 
mutations, related to therapeutic resistance caused by the aberrant activation of ERα 
[26–31]. Previous reports showed the genetic alteration of ERα were suggested to relate 
with endocrine therapy resistance. Especially in some part of aromatase resistant 
breast cancers, the mutations of ERα LBD were found to be the cause of aberrant 
activation of ERα and less sensitivity to endocrine therapy, which lead to therapy 
resistance. I focused on four major ERα LBD mutation hot spots [28], but I could not 
detect mutations (Figs. 3A,B). These results suggested that the fulvestrant-resistant 
cell lines appeared to proliferate in an estrogen-ERα–independent manner. 
 
4.4 Fulvestrant-resistant cell lines and ERα expression 
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As both established fulvestrant-resistant cell lines were not sensitive to estrogen or AEs, 
I analyzed ERα mRNA and protein expression status by real-time RT-PCR and Western 
blotting, respectively. In contrast to the effects of short-term exposure to fulvestrant (Fig. 
1C), both resistant cell lines exhibited severely diminished ERα mRNA expression (Fig. 
4A). To determine whether the decline of ERα mRNA expression reflected promoter 
activity, I measured transcription products from individual promoters using real-time 
RT-PCR with specific primers for promoters A–D, which were the predominant 
contributors to ERα transcription in previous study [24,32,33]. Critically, promoter A 
produced greater quantities of transcripts in parental cell lines, and fulvestrant-resistant 
cell lines displayed downregulation of transcripts from promoter A, suggesting that 
promoter A transcripts were necessary for ERα expression (Fig. 4B). These results 
suggested the cell lines lost ERα via the repression of gene transcription rather than 
mRNA degradation. The loss of ERα mRNA by repression of transcription resulted in the 
loss of ERα protein and its target genes (PgR: Progesterone Receptor, and pS2) expression 
(Figs. 4C-D). I conclude that both fulvestrant-resistant cell lines had diminished ERα 
protein expression and downregulated ERα transcription. 
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4.5 Epigenetic changes of ERα gene promoter regions  
As no genetic alterations of ERα related to therapeutic resistance were uncovered (Figs. 
3A, B), I focused on epigenetic alteration of the ERα gene to elucidate the mechanism of 
ERα gene transcription repression. The DNA methylation statuses of five CpG sites 
within or near the ERα gene promoter region were analyzed using bisulfite sequencing 
(Fig. 5A). Surprisingly, almost all CpG sites were methylated in MFR cells compared to 
the findings in the parent cell line, and in particular, region 1 was remarkably 
methylated. On the contrary, TFR cells did not exhibit remarkable DNA methylation 
pattern changes compared to parent cell line, and DNA methylation levels were not 
elevated in analyzed regions (Fig. 5B). Region 1 includes promoter A, a dominant 
promoter of ERα, and I suggested that MFR cells lost ERα expression due to DNA 
methylation of ERα promoters, especially promoter A. For confirmation, I treated the 
cells with Aza, a DNA methylation inhibitor. Following Aza treatment, DNA methylation 
level of region 1 was significantly reduced in MFR cells (Fig. 5C). Furthermore, ERα 
mRNA and protein expression was restored in MFR but not TFR cells (Figs. 5D-E). I 
concluded that ERα was lost in MFR cells due to DNA methylation of the ERα promoter. 
 
4.6 HDAC inhibitors did not restore ERα expression in TFR cells. 
To address the mechanisms by which ERα was repressed in TFR cells, next I focused on 
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the histone modulation of ERα gene. I used two specific histone deacetylase inhibitors 
(Entinostat, Vorinostat). They are expected to conquer endocrine therapy resistant breast 
cancers and one of the mechanisms to conquer resistance is suggested to re-express the 
aberrantly repressed genes. Thus I treated TFR cells with indicated drugs for 48h, then 
harvested (Fig. 6A). Western blot analysis showed that the specific histone deacetylase 
inhibitors entinostat and vorinostat did not restore ERα expression in TFR cells (Fig. 6B). 
This showed that histone deacetylation was not the essential event in TFR cells to 
repress ERα expression. 
 
4.7 The difference in ERα expression plasticity 
There were dramatic differences in ERα gene epigenetic status between MFR and TFR 
cells, and I assessed the plasticity of ERα expression in these cell lines. I cultured these 
cell lines in fulvestrant-withdrawn, estrogen-supplied medium for an extended period 
and monitored ERα mRNA and protein expression. The results illustrated the difference 
between MFR and TFR cells regarding ERα plasticity. I noticed that ERα mRNA and 
protein expression was restored in TFR cells, but not in MFR cells (Figs. 7A-B). Moreover, 
ERα target gene expression also followed ERα expression. Eventually, TFR cells, but not 
MFR cells, were re-sensitized to AEs (Figs. 7C-D). Because DNA methylation is a stable 
regulatory mechanism, MFR did not re-express ERα under fulvestrant-withdrawn 
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conditions. By contrast, TFR cells did not exhibit remarkable changes in DNA 
methylation patterns, and these cells had greater flexibility in ERα expression. 
 
4.8 MFR switched their survival signaling from ERα to Akt/MAPK pathways 
Following the above results, it was suggested that MFR cells did not depend on ERα 
signaling because of the rigid repression of ERα. I, also with predecessors of affiliate 
laboratory, next addressed the activation of intracellular signaling factors, such as 
MAPK and Akt that helped to maintain MFR proliferation. The expression of 
phosphorylated MAPK (p-MAPK) and Akt (p-Akt) appeared to be increased in MFR cells 
compared to the parental levels, although fulvestrant treatment hardly affected their 
phosphorylation status. p-MAPK and p-Akt levels were approximately 2- and 1.4-fold 
higher, respectively, than the parental levels according to densitometric quantification. 
Next, we assessed the efficacy of selective inhibitors of MAPK and Akt pathways. MFR 
cells were significantly more sensitive to the ERK inhibitor U0126 and the Akt inhibitor 
LY294002 than the parental cells. Furthermore, inhibitor of mTOR, Everolimus, which 
targets downstream of Akt, effectively repressed the growth of MFR cells (Fig. 8A). 
Examining the upstream signals of these pathways, HER family members and Src were 
involved and important to MFR cells growth. We noticed 2-fold upregulation of HER2 
and HER3 mRNA expression by real-time RT-PCR (Fig. 8B), and the pan-HER family 
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inhibitor lapatinib effectively repressed MFR cell growth (Fig. 8C). Previous reports 
suggested that Src complexed with HER family members to activate downstream 
pathways [34,35]. The Src inhibitor dasatinib also effectively blocked MFR cell growth 
(Fig. 8C), thus we concluded that signaling in MFR cells shifted from ERα to HER/Src-
Akt/MAPK pathways. 
 
4.9 TFR differed from MFR in their survival signaling 
On the other hand, we also have examined TFR cells in same way as MFR cells. The 
expression of phosphorylated MAPK (p-MAPK) and Akt (p-Akt) appeared to be no 
significant difference in TFR cells compared to the parental levels. We also assessed the 
efficacy of selective inhibitors of MAPK and Akt pathways, otherwise TFR cells were less 
sensitive to the ERK inhibitor and the Akt inhibitor than the parental cells (Fig. 9A). 
Examining the upstream signals of these pathways, we noticed upregulation of HER2 
mRNA expression by real-time RT-PCR (Fig. 9B). However, the pan-HER family inhibitor 
lapatinib did not specifically inhibit growth of TFR cells (Fig. 9C). We could not find 
particular change in MAPK and PI3K activation nor specific inhibitors for TFR growth. 
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5. Discussion 
Most breast cancers express ERα, and endocrine therapy is a more effective and less toxic 
therapy for these patients compared to chemotherapy. Concerning about adverse effects 
though varying in type of endocrine therapy, they commonly target estrogen―ERα axis 
and therefore the menopausal symptoms, such as hot flashes, are mostly common 
adverse effects. The SERD fulvestrant blocks ERα dimerization and promotes ERα 
protein degradation, resulting in the inhibition of ERα function. Obtained results in this 
study confirmed the effect of fulvestrant, which inhibits ERα protein expression and 
function. Fulvestrant has a steroidal structure and high affinity with the cellular 
membrane and matrix, as well as high chemical stability, resulting in long-lasting effects 
[16,36,37]. In vitro, I demonstrated that fulvestrant treatment results in the repression 
of ERα protein expression, although short-term exposure did not affect ERα mRNA 
expression. This finding indicated that ERα transcription was not altered in this period, 
differing from the effects of long-term exposure. 
As recent clinical trials demonstrated the better efficacy of fulvestrant treatment than 
AIs for ERα-positive post-menopausal breast cancers, this drug could possibly be used in 
the first-line treatment of patients with ERα-positive breast cancer. Therefore, the 
problem of acquired resistance to fulvestrant is a critical issue that must be resolved. 
Thus fulvestrant-resistant cell lines were established by predecessors of affiliate 
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laboratory from typical luminal-like breast cancer cell lines, MCF-7 and T-47D to 
elucidate the mechanisms of fulvestrant resistance. I found out that these cells exhibited 
a loss of ERα activity and protein expression as well as ERα mRNA expression, 
suggesting that ERα transcription was suppressed. These changes were not observed 
following short-term fulvestrant exposure. Previous report from other laboratory 
indicated the loss of ERα during endocrine therapy [10], which is considered one of the 
mechanisms of endocrine therapy resistance. Thus, the regulation of ERα expression is 
one of the keys for addressing resistance to endocrine therapy.  
Our and other laboratories suggested that ERα has multiple promoters, and the usage 
rates of these promoters differ in various organs [24,38]. It was reported that high usage 
of ERα promoter C is related to tamoxifen resistance [39]. In fulvestrant-resistant cell 
lines in our laboratory, I elucidated the usage of all ERα promoters was diminished; in 
particularly, usage of promoter A was dramatically decreased compared to that in the 
parent cells. Promoter A neighbors the first exon of ERα and features CpG islands, and 
the usage of promoter A is well correlated with ERα expression in clinical breast cancers 
[24]. It is the dominant promoter for regulating ERα transcription. To address the 
mechanism of ERα gene downregulation, I focused on epigenetic regulation, especially 
the DNA methylation level of gene promoter regions. The methylation level of promoter 
regions was negatively correlated with the expression of genes of interest [40]. I assessed 
24 
the DNA methylation level of ERα promoter regions to elucidate the downregulation 
mechanism of ERα in fulvestrant-resistant cell lines. There were considerable differences 
in the DNA methylation status of ERα. Specifically, MFR cells exhibited high methylation 
levels in all assessed regions, whereas differences were noted between TFR cells and the 
parental cells. ERα protein and mRNA expression was restored in MFR cells following 
treatment with the DNA methylation inhibitor Aza. Together, these results suggested 
there are at least two mechanisms of ERα downregulation in fulvestrant-resistant cell 
lines. The difference in epigenetic regulation affects the stability and flexibility of 
transcription regulation [40,41]. DNA methylation resulted in rigid and stable silencing 
of genes of interest, but histone modulation is associated with greater flexibility. This 
might explain the plasticity of ERα expression in fulvestrant-resistant cell lines. 
Specifically, ERα expression was not restored in MFR cells because of DNA methylation, 
whereas TFR cells re-expressed ERα. The mechanisms by which ERα was repressed in 
TFR cells are still unclear, and I observed that treatment with the specific histone 
deacetylase inhibitors entinostat and vorinostat did not restore ERα expression in TFR 
cells. Once ERα was re-expressed in TFR cells, they proliferated in an estrogen-ERα–
dependent manner that was inhibited by anti-estrogens. These results suggested that 
the epigenetic mechanisms for ERα silencing will be considered in future therapeutic 
strategies to combat fulvestrant resistance. Regarding the established cells, TFR cells 
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may be sensitive to an alternative endocrine therapy, but MFR cells may not be affected 
by additional endocrine therapy.  
Therefore, another therapeutic strategy, such as molecular targeting therapy, should be 
considered for MFR cells. Elucidating the alternative pathways on which MFR growth 
depends is an important concern for the treatment of ERα-negative, endocrine therapy-
resistant breast cancers using optimal molecular targeted drugs. In MFR cells, Akt and 
MAPK signals were activated, and HER2 and HER3 mRNA expression was upregulated. 
Specific inhibitors of these pathways effectively inhibited MFR cell growth. Lykkesfeldt 
and colleagues used an ERα-negative fulvestrant resistant cell line generated from T-
47D cells and reported that Src pathway activation was involved in fulvestrant 
resistance [17], and I confirmed this finding in an MCF-7–derived ERα-negative 
fulvestrant-resistant cell line. The growth of MFR cells was also effectively inhibited by 
the Src inhibitor dasatinib, suggesting that activation of Src family members might be 
an important event in ERα-repressed fulvestrant-resistant cells.  
In respect of resistant mechanism, I also note that there are considerable difference 
between fulvestrant and aromatase inhibitors based on molecular mechanisms. Our 
laboratory has reported at least 6 types of AI resistant model cell lines and classified 3 
types of AI resistant mechanisms in brief : Ⅰ Alternative ERα ligand dependent 
mechanism, Ⅱ Ligand independent, ERα dependent mechanism, Ⅲ ERα independent 
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mechanism [42]. In AI resistance, ERα has still a pivotal role in some cases, otherwise in 
fulvestrant resistance, ERα is no more targetable protein in fulvestrant resistant cell 
lines established in this study. 
 
6. Conclusion 
In conclusion, ERα repression is one of the causative factors of fulvestrant resistance, 
and the mechanisms by which ERα is repressed might be influenced by treatment after 
the development of fulvestrant resistance. Although further investigations are necessary, 
I surmise that methylation of the ERα promoter region may be a predictive marker for 
selecting the appropriate treatment after resistance appears.  
This is the first report to address the mechanisms of ERα repression in fulvestrant-
resistant cells lines. There is heterogeneity including at least two mechanisms: DNA 
methylation-related and DNA methylation-unrelated. This might influence the choice of 
therapy after resistance develops, and this is valuable information to consider when 
choosing subsequent therapies.  
These findings provide clues for treating endocrine therapy-resistant breast cancers, 
especially cases that are converted from ERα-positive to ERα-negative. Elucidating the 
mechanisms of ERα transcription and expression regulation might provide information 
for selecting the proper therapeutic strategy. Furthermore, I suppose that ERα has a 
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pivotal role in its characteristics in luminal-like breast cancers, and the loss of ERα 
results in poor prognosis; thus, modulating ERα transcription and expression is a 
challenging strategy for avoiding tragic outcomes in patients with endocrine therapy-
treated breast cancers. 
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8. Figure legends 
Figure 1.  
Short-term fulvestrant exposure diminished estrogen receptor α (ERα) protein but not 
mRNA expression. 
A: Schematic figure describing the time-course between fulvestrant treatments to 
harvest. MCF-7 and T-47D cells were treated with 100 nM fulvestrant for 48 h followed 
by withdrawal via medium replacement. Cells were then harvested after 0 days, 3 days, 
1 week, and 2 weeks to analyze ERα protein and mRNA levels. B: The change of ERα 
protein levels. MCF-7 and T-47D cells were harvested at various times and subjected to 
Western blot analysis. β-Tubulin expression is shown as an internal control. C: The 
change of ERα mRNA levels analyzed using real-time RT-PCR. The data were normalized 
to an internal control (RPL13A), All data are presented as the mean ± SD (n = 3). 
 
Figure 2. 
Establishment of fulvestrant-resistant cell lines. 
A: Establishment of fulvestrant-resistant cells. MCF-7 and T-47D cells were transfected 
with estrogen receptor element (ERE)-green fluorescent protein (GFP) reporter 
plasmids as described previously. The cells were cultured in fulvestrant-supplied 
medium (final concentration: 10 nM) for 6 months to establish fulvestrant-resistant cell 
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lines. B: Picture of GFP fluorescence monitoring ERE activity obtained using a BZ9000 
(exposure time: 1 s). The scale bar is presented in the lower right in each picture. C: 
The sensitivity to anti-estrogens was measured via a cell proliferation assay. Cells were 
treated with vehicle, 100 nM fulvestrant (Fulv), or 1 μM tamoxifen (Tam) for 4 days. 
The values relative to the vehicle control are shown, and data are presented as the 
mean ± SD (n = 3). D: Estrogen-medicated cell proliferation. Cells were treated with the 
indicated concentrations of estradiol (E2) or vehicle for 4 days. The relative 
proliferation activity is the ratio compared to the vehicle control, and the data are 
presented as the mean ± SD (n = 3). **P < 0.01. 
 
Figure 3. 
DNA sequencing for estrogen receptor α ligand-binding domain mutations.  
A. Scheme of mutation hot spot in ERα ligand binding domain. B. Sequence results of all 
cell lines concerning indicated hot spot. 
 
Figure 4.  
Fulvestrant-resistant cell lines displayed downregulated ERα gene expression.  
A: Total ERα mRNA expression in fulvestrant-resistant cells and their parental cell 
lines as determined by real-time RT-PCR. Data were normalized by an internal control 
38 
(RPL13A). The relative expression level is the ratio compared to that in parental cells, 
with data presented as the mean ± SD (n = 3). B: (Upper) Schematic figure of estrogen 
receptor α (ERα) promoter sites. (Lower) Transcription activities from each promoter of 
the ERα gene were determined using real-time RT-PCR with promoter-specific primers. 
The data were normalized by an internal control (β-actin). All data are presented as the 
mean ± SD (n = 3). C: Total ERα protein expression in the indicated cell lines were 
determined by Western blot analysis. MCF-7 and T-47D cells, which were pre-treated 
with 100 nM fulvestrant for 48 h, were named “MCF-7+Fulv 100 nM” and “T-47D+Fulv 
100 nM,” respectively. β-Tubulin is shown as an internal control. D: PgR and pS2 
mRNA expression in fulvestrant-resistant cells and their parental cells as determined 
by real-time RT-PCR. Data were normalized by an internal control (RPL13A). The 
relative expression level is the ratio compared to that of the parental cells, with data 
presented as the mean ± SD (n = 3). 
 
Figure 5.  
DNA methylation status of estrogen receptor α (ERα) gene promoter regions differs 
between MFR and TFR cells.  
A: DNA methylation status of ERα promoter regions in each cell line was analyzed using 
bisulfite direct sequencing. Vertical lines indicate CpG sites, and the five left–right 
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arrows indicate the examined regions. B: Methylation status is shown for each CpG site 
in the examined regions. Methylation levels were provisionally quantified according to 
the wave patterns of sequences and indicated as three grades. C: DNA methylation level 
of ERα promoter region 1 in MFR cells were quantitated by colony sequencing. Vertical 
bars indicate methylation levels of each CpG in region 1. Control group was treated with 
PBS for 72h and Aza group was treated with 2.5 μM 5′-aza-2′-deoxycytidine (Aza) for 72h. 
D: ERα protein expression in the indicated cell lines was determined by Western blot 
analysis. MFR and TFR cells were treated with 1 μM Aza for 1–3 days. β-Tubulin is 
shown as an internal control. E: Monitoring of ERα mRNA expression in fulvestrant-
resistant cells treated with 1 μM Aza for 1–3 days by real-time RT-PCR. Data were 
normalized by an internal control (RPL13A) and presented as the mean ± SD (n = 3). I 
used 2.5 μM dose of Aza for DNA methylation analysis (Fig. 4C) and 1 μM dose for mRNA 
– Protein expression analysis (Figs. 4D-E) because 2.5 μM dose is known to degrade ERα 
mRNA stability [43]. 
 
Figure 6. 
HDAC inhibitors did not restore ERα expression in TFR cells.  
A: Drugs and experimental conditions. Cells were treated with drugs for 48h, then 
harvested. B: Total ERα protein expression in the indicated conditions was determined 
40 
by Western blot analysis. β-Tubulin is shown as an internal control.  
 
Figure 7.  
TFR, but not MFR, cells exhibited plasticity regarding estrogen receptor α (ERα) gene 
expression and ERα-dependent growth.  
A: The change of ERα mRNA expression in fulvestrant-resistant cells under fulvestrant-
withdrawn, 10 nM estradiol (E2)-supplied conditions monitored by real-time RT-PCR 
following the indicated time-course. Data were normalized by an internal control 
(RPL13A) and presented as the mean ± SD (n = 3). B: Monitoring the change in ERα 
protein expression change in fulvestrant-resistant cells cultured under the same 
condition described in Figure 7A by Western blot analysis. β-Tubulin is shown as an 
internal control. C: Expression of the ERα target genes PgR and pS2 were monitored by 
real-time RT-PCR following the indicated time-course, normalized by an internal control 
(RPL13A), and presented as the mean ± SD (n = 3). D: The sensitivity to anti-estrogens 
was measured by cell proliferation assays. Fulvestrant-resistant cell lines that were 
grown under fulvestrant-withdrawn and 10 nM estradiol (E2)-supplied conditions for the 
indicated periods were treated with vehicle, 100 nM fulvestrant (Fulv), or 1 μM 
Tamoxifen (Tam) for 4 days. The values relative to the vehicle control were shown, and 
data are presented as the mean ± SD (n = 3). 
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Figure 8.  
The Akt/MAPK pathway was activated in MFR cells.  
A: Western blot analysis and cell proliferation assay comparing MCF-7 and MFR cells. 
All cells were cultured with maintained medium, which were changed to the medium 
containing indicated drugs, and incubated for 72h. Whole lysates were subjected to 
Western blot analysis to detect the indicated proteins using specific antibodies. β-Tubulin 
is shown as an internal control. p-MAPK and p-Akt expression was quantified by 
densitometry. The sensitivity to the indicated drugs was analyzed by cell proliferation 
assays. All cells were cultured with RPMI1640+5% FCS medium and treated with the 
indicated concentrations of drugs (0 as vehicle control) for 4days. The values are 
presented relative to the vehicle control and as the mean ± SD (n = 3). *P < 0.05, **P < 
0.01. B: HER2 and HER3 mRNA expression in MCF-7 and MFR cells as determined by 
real-time RT-PCR. Data were normalized by an internal control (RPL13A). The relative 
expression level is the ratio compared to that in MCF-7 cells, and data are presented as 
the mean ± SD (n = 3). C: The sensitivity to lapatinib and dasatinib was analyzed by cell 
proliferation assays. The cells were cultured with RPMI1640+5% FCS medium and 
treated with the indicated concentrations of drugs (0 as vehicle control) for 4 days. The 
values are shown relative to the vehicle control, and data are presented as the mean ± 
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SD (n = 3). **P < 0.01. 
 
Figure 9. 
Intracellular pathway and growth inhibition analysis of TFR cells.  
A: Western blot analysis and cell proliferation assay comparing T-47D and TFR cells. All 
cells were cultured with maintained medium, which were changed to the medium 
containing indicated drugs, and incubated for 72h. Whole lysates were subjected to 
Western blot analysis to detect the indicated proteins using specific antibodies. β-Tubulin 
is shown as an internal control. The sensitivity to the indicated drugs was analyzed by 
cell proliferation assays. All cells were cultured with RPMI1640+5% FCS medium and 
treated with the indicated concentrations of drugs (0 as vehicle control) for 4days. The 
values are presented relative to the vehicle control and as the mean ± SD (n = 3). B: 
HER2 and HER3 mRNA expression in T-47D and TFR cells as determined by real-time 
RT-PCR. Data were normalized by an internal control (RPL13A). The relative expression 
level is the ratio compared to that in T-47D cells, and data are presented as the mean ± 
SD (n = 3). *P < 0.05. C: The sensitivity to lapatinib and dasatinib was analyzed by cell 
proliferation assays. The cells were cultured with RPMI1640+5% FCS medium and 
treated with the indicated concentrations of drugs (0 as vehicle control) for 4 days. The 
values are shown relative to the vehicle control, and data are presented as the mean ± 
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SD (n = 3).   
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10. Tables 
Table 1 
Primer and probe sets for real-time reverse transcription polymerase chain reaction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    Sequence 5′→3′ 
Total ER Forward CTCCCACATCAGGCACAT 
 Reverse CTCCAGCAGCAGGTCATA 
ER promoter A Forward CTGTGCTCTTTTTCCAGGTG 
 Reverse AGGGTCATGGTCATGGTC 
 Probe CCGGTTTCTGAGCCTTCTGCCC 
ER promoter B Forward CAGCGACGACAAGTAAAGTG 
 Reverse Same as promoter A 
 Probe Same as promoter A 
ER promoter C Forward TCTTGATCCAGCAGGGTG 
 Reverse Same as promoter A 
 Probe Same as promoter A 
ER promoter D Forward CACCTGAGAGAGCCAGTG 
 Reverse Same as promoter A 
 Probe Same as promoter A 
PgR Forward AGCTCACAGCGTTTCTATCA 
 Reverse CGGGACTGGATAAATGTATTC 
pS2 Forward TCCCCTGGTGCTTCTATCCTAA 
 Reverse ACTAATCACCGTGCTGGGGA 
RPL13A Forward CCTGGAGGAGAAGAGGAAAG 
 Reverse TTGAGGACCTCTGTGTATTT 
β-actin Forward GAGTACTTGCGCTCAGGAGGA 
 Reverse ACGTGGACATCCGCAAAGA 
 Probe CAATGATCTTGATCTTCATTGTGCTGGGTG 
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Table 2 
Primer and probe sets for bisulfite sequencing assays 
    Sequence 5′→3′ 
ER promoter 
region1  
Forward GTTGTGTTTGGAGTGATGTTTAAGTT 
  Reverse CAATAAAACCATCCCAAATACTTTA 
ER promoter 
region2 
Forward GGAAGGGTTTATTTATTTTGGGAGTA 
  Reverse TAACATTAACTTAAACATCATCACTCC 
ER promoter 
region3 
Forward TTGGGTGTTTGGGATAGTAATTAAA 
  Reverse CTTAATCCCATTAAAAATTCTCATA 
ER promoter 
region4  
Forward TGGTTGTGTTATATTGTTTT 
  Reverse TCTCCCTACTAAAATACAAACACTAACCAA 
ER promoter 
region5 
Forward AGTTTTTTTGTGAATTATGT 
  Reverse CTCATACTACTCATAAACTC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
